Does OLAPARIB Cause Performance status decreased? 9 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Performance status decreased have been filed in association with OLAPARIB (Lynparza). This represents 0.1% of all adverse event reports for OLAPARIB.
9
Reports of Performance status decreased with OLAPARIB
0.1%
of all OLAPARIB reports
1
Deaths
5
Hospitalizations
How Dangerous Is Performance status decreased From OLAPARIB?
Of the 9 reports, 1 (11.1%) resulted in death, 5 (55.6%) required hospitalization, and 1 (11.1%) were considered life-threatening.
Is Performance status decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Performance status decreased?
BACLOFEN (156)
LENALIDOMIDE (118)
PACLITAXEL (112)
BEVACIZUMAB (103)
SODIUM OXYBATE (103)
CARBOPLATIN (100)
DEXAMETHASONE (80)
CAPECITABINE (75)
NIRAPARIB (75)
LUMATEPERONE (68)
Which OLAPARIB Alternatives Have Lower Performance status decreased Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL